Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Central Nervous System Tumors
- Surgical Oncology
- Immunotherapy
- Cervical Cancer
- Radiation Oncology
- Leukemia
- Gynecological Cancers
- Haemato-Oncology
Abstract
Citation: Clin Oncol. 2017;2(1):1250.DOI: 10.25107/2474-1663.1250
Benefits of Metastasectomy in Esophagogastric Cancer
MacCormick S, Chong KC, Sullivan HO, Hamill M and MacCormick R
Department of Oncology, Cape Breton Regional Hospital, Sydney, Nova Scotia, Canada
*Correspondance to: MacCormick R
PDF Full Text Case Report | Open Access
Abstract:
Background: Esophagogastric cancer is the second most common cause of cancer related deaths worldwide and often presents late with approximately 32% of US patients presenting with distant metastases. The current guidelines for metastases of gastric cancer involve palliative chemotherapy and supportive measures. However, the median overall survival with these guidelines is less than 1 year. Performing a gastrectomy, along with metastasectomy and chemotherapy shows the highest median overall survival of 28.0 months for metastatic gastric cancer. The aim of this systematic review is to determine whether performing metastasectomies increases overall, 1year and 3year survival in metastatic esophagogastric carcinoma.Methods: A systematic review was performed. Inclusion and exclusion criteria were developed, specific outcomes were identified (overall, 1 and 3 year survival for esophagogastric cancer with and without metastasectomies) and a search strategy with key words for Embase and Google Scholar was employed.Results: 37 articles were found through the Embase database search and 20 additional sources were identified via independent Google Scholar searches. After careful review of the titles, abstracts and full texts by 2 separate reviewers, 6 articles were included for systematic review. The median overall survival, 1-year survival and 3-year survival were greater for patients who received gastrectomy with metastasectomy compared to gastrectomy without metastasectomy, with the exception of study that did not concur with a greater 1-year survival in metastasectomy patients.Conclusions: This systematic review, suggests that surgery for resection of oligometastases improves prognosis. However, randomized, larger scale studies are recommended.
Keywords:
Cite the Article:
MacCormick S, Chong KC, Sullivan HO, Hamill M, MacCormick R. Benefits of Metastasectomy in Esophagogastric Cancer. Clin Oncol. 2017; 2: 1250.
